Literature DB >> 16399597

Modulation of graft-versus-host disease: role of regulatory T lymphocytes.

Allan D Hess1.   

Abstract

Graft-versus-host (GVH) disease (GVHD) continues to be a major life-threatening complication after allogeneic bone marrow transplantation. Considerable progress has been made elucidating the pathophysiology of acute GVHD. Mature donor T cells transferred along with the marrow graft directly recognize antigenic differences on antigen-presenting cells of the host. Once activated, donor antihost-specific T cells can mediate tissue destruction. Interestingly, the failure to clonally delete autoreactive T cells in the thymus can also lead to an autoimmune syndrome mimicking the pathology of GVHD. Negative selection in the thymus may be compromised either by damage to the thymic epithelium (because of a direct attack by donor antihost alloreactive T cells) or by the use of immunosuppressive drugs that inhibit clonal deletion. An important component underlying GVHD mediated by either alloreactive or autoreactive T cells is the absence of a competent peripheral regulatory system. Studies in animal model systems clearly indicate that regulatory T cells play a vital role in down-regulating GVHD and are critically important for the establishment of active dominant tolerance to both allo- and self-major histocompatibility complex antigens. Although multiple populations of cells appear to participate in this process, CD4(+) regulatory T cells that innately express CD25(+) appear to orchestrate the regulatory control of the immune response. Evidence for regulatory T cells in clinical bone marrow transplantation, however, remains rudimentary. The recent identification that CD4(+)CD25(+) regulatory T cells preferentially express the Foxp3 nuclear transcription factor and the development of molecular reagents to isolate antigen-specific T cells have provided unique opportunities to explore immunoregulatory mechanisms after clinical marrow transplantation. Recent studies in recipients of clinical bone marrow transplantation suggest that antigen-specific CD4(+)CD25(+)Foxp3(+) T cells play a vital role in the regulatory control of GVH reactions mediated by both alloreactive and autoreactive lymphocytes. These regulatory T cells also appear to facilitate the establishment of donor antihost and donor antidonor (self) tolerance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399597     DOI: 10.1016/j.bbmt.2005.11.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood.

Authors:  Huahua Fan; Jie Yang; Jun Hao; Yana Ren; Liang Chen; Guiping Li; Rufeng Xie; Yiming Yang; Feng Gao; Mingyao Liu
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.

Authors:  S-Y Lu; K-Y Liu; D-H Liu; L-P Xu; X-J Huang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

3.  Clonotypic analysis of T cell reconstitution after haematopoietic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency.

Authors:  H Okamoto; C Arii; F Shibata; T Toma; T Wada; M Inoue; Y Tone; Y Kasahara; S Koizumi; Y Kamachi; Y Ishida; J Inagaki; M Kato; T Morio; A Yachie
Journal:  Clin Exp Immunol       Date:  2007-03-21       Impact factor: 4.330

4.  Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graft-versus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases.

Authors:  Paolo Perseghin
Journal:  Transfus Med Hemother       Date:  2007-12-21       Impact factor: 3.747

5.  Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.

Authors:  Jane M Fall-Dickson; Sandra A Mitchell; Susan Marden; Edward S Ramsay; Jean-Pierre Guadagnini; Tianxia Wu; Lena St John; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-06       Impact factor: 5.742

6.  Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.

Authors:  Sheng F Cai; Xuefang Cao; Anjum Hassan; Todd A Fehniger; Timothy J Ley
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

7.  Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.

Authors:  P Cipriani; P Di Benedetto; V Liakouli; B Del Papa; M Di Padova; M Di Ianni; A Marrelli; E Alesse; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

Review 8.  Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?

Authors:  Rainer Storb; Joseph H Antin; Corey Cutler
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

9.  Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.

Authors:  Emmanuel Zorn; Mehrdad Mohseni; Haesook Kim; Fabrice Porcheray; Allison Lynch; Roberto Bellucci; Christine Canning; Edwin P Alyea; Robert J Soiffer; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

10.  Toxic Epidermal Necrolysis and Graft-versus-Host Reaction: Revisiting a Puzzling Similarity.

Authors:  G E Piérard; T Hermanns-Lê; P Paquet; A F Rousseau; P Delvenne; C Piérard-Franchimont
Journal:  ISRN Dermatol       Date:  2013-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.